Safe practice and nursing care of patients receiving oral anticancer medicines: a position statement from UKONS

Catherine Oakley, Chemotherapy Nurse Consultant, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Elaine Lennan, Consultant Chemotherapy Nurse, Southampton University Hospital Trust, Southampton, UK
Helen Roe, Consultant Cancer Nurse, North Cumbria University Hospitals NHS Trust, Cumbria, UK
Olive Craven, Nurse Clinician, Christie Hospital, Manchester, UK
Karen Harrold, Chemotherapy and IV Access Clinical Nurse Specialist, Mount Vernon Cancer Centre, Middlesex, UK
Cheryl Vidall RGN, Clinical Risk and Practice Development Manager, Healthcare at Home Ltd, Staffordshire, UK

Published originally in ecancermedicalscience (Oakley C, Lennan E, Roe H et al. Safe practice and nursing care of patients receiving oral anticancer medicines: a position statement from UKONS. ecancer 2010; 4: 177. DOI: 10.3332/ecancer.2010.177.)

Proposed Objective

This position statement has been formulated by oncology nurses from the UK Oncology Nursing Society (UKONS) to provide guidance for nurses on safe practice with oral anticancer medicines. The ultimate aim is to ensure that patients are not only well informed and capable of managing their oral anticancer medicines but also supported safely and effectively while they are receiving these treatments.

Background

The past decade has seen a change in the way many patients with cancer are managed. There has been a huge increase in the number of oral anticancer medicines licensed for the treatment of solid and haematological tumours, and this has led to a rapid escalation of their use. During 2006–2007, for example, nearly 24 million doses of oral anticancer medicines were used in England alone.¹

The enthusiastic uptake of oral anticancer medicines has been driven by the advantages they offer to patients and to the NHS, in terms of toxicity management, convenience of delivery and cost-effectiveness. Compared with intravenous (IV) cancer treatments, oral drugs require fewer NHS resources. Patients may not need admission to the ward or day unit for cannulation and administration of drugs (unless receiving IV anticancer medicines in combination with the oral drug). This helps to reduce the burden on inpatient beds and on nursing and pharmacy staff in already stretched chemotherapy units. Furthermore, patients reportedly prefer oral to IV anticancer medication because of the convenience of self-administering treatment at home.²

However, while chemotherapy services recognise standards advocating the administration of IV cancer treatments by appropriately trained nursing staff (as outlined in the Manual for Cancer Services³), a recent survey of UK pharmacists suggests that procedures for the administration of oral anticancer medicines are less rigorous.⁴ This has worrying consequences: in January 2008, the National Patient Safety Agency (NPSA)
Principles of safe practice

In general, the principles of safe practice for administration of oral anticancer medicines should be the same as those for IV treatments, as outlined in the Manual for Cancer Services. Since patients are required to manage their own treatments away from hospital, additional safe practice procedures are needed to ensure that patient education is optimal and patients are competent in managing their treatment.

Standards, protocols and guidelines

Guidelines and protocols are required for oral anticancer medications, covering the supply of treatment (e.g. procedures for ensuring patients are adequately assessed and supported to manage oral therapies, and verifying the patient’s identity before treatment is dispensed). Providers should also ensure those managing patients on oral anticancer medications have the appropriate specialist skills and knowledge to ensure safe administration.

Training

Within a clinical chemotherapy service, registered nurses who administer anticancer medicines should have undertaken degree level cancer-related studies, including one or more modules in chemotherapy, and their competence should be assessed annually. In relation to oral treatment, the training programme should include the following:

• Knowledge of oral anticancer medication protocols, as detailed in the network list of approved regimens
• Cancer drug administration
• Establishing and running nurse-led clinics
• Communication skills
• Assessment of patients receiving anticancer medication, which is incorporated into an ongoing holistic assessment
• Assessment of common anticancer medication side effects, including myelosuppression, nausea, vomiting, stomatitis, diarrhoea, hypertension, lethargy and palmar-plantar erythrodysesthesia
• Cancer treatment side effects that constitute a medical emergency, for example neutropenic sepsis, thrombosis and angina
• Health and safety aspects of anticancer medication administration, including storage, safe handling and waste disposal

Prescribing

The prescribing policy for oral anticancer medicines should be the same as for IV anticancer medication, as outlined in the Manual for Cancer Services. All oral anticancer medicines should be prescribed only in the context of a written protocol and treatment plan.

Nurse prescribing and treatment initiation

In line with current health policy, nursing and pharmacy roles are being expanded to take on responsibilities that were traditionally the

Definitions

The commonly understood definition of oral anticancer medicines covers all drugs with direct anti-tumour activity, orally administered to cancer patients. The definition includes traditional cytotoxic drugs as well as targeted therapies (see Table 1), but does not include hormonal or anti-hormonal agents, such as tamoxifen or anastrozole. Drugs fitting this definition are included in the remit of this document.
role of doctors, such as prescribing. Nurse prescribing in oncology enables the patients to get the required medication on time and may allow patients to be managed nearer to home.\(^1\) It facilitates a holistic approach to patient care, and it enables sharing of the prescribing workload in busy chemotherapy clinics.\(^7,12\)

The *Manual for Cancer Services*\(^1\) states that oral anticancer treatment should be initiated by a cancer specialist. These standards have been adapted in certain networks to allow non-medical prescribers to prescribe the first cycle (for example, The Christie NHS Foundation Trust and Southampton University Hospitals Trust). Variations in local policy must be acknowledged and underpinned by appropriate continuous professional development and robust governance arrangements.

Regardless of whether the prescriber is medical or non-medical, it is important that he or she has access to and follows local written protocols, including guidance on monitoring and treatment of toxicity.\(^1,7\)

**Prescriptions**

Where possible, electronic prescribing systems should be used because these have been shown to help standardise protocol-based prescribing and reduce the risk of errors.\(^8\) If an approved and validated electronic prescribing system is unavailable,\(^4\) all prescriptions of anticancer medicines should be computer-generated, at least when using regimens from the agreed list.\(^3\) All of these prescriptions should be checked and authorised by an appropriately trained pharmacist.\(^3\)

**Prescription verification procedures**

Nurses are well placed to check patient suitability for oral anticancer medicines, for example by noting whether cognitive state, social isolation or presence of severe dysphagia prevents administration of anticancer medication by this route.\(^7\) It is important that label directions are clear and unambiguous and that they include, where relevant, the intended period of treatment, start and stop dates, any special instructions, and appropriate information about the need for safe handling.\(^9\)

When patients are self-administering oral anticancer medicines in their own home, it is important that they:\(^1\)

- Are aware of the required monitoring arrangements
- Have access to information in the written protocol and treatment plan from the hospital where treatment was initiated
- Have access to advice from an appropriately qualified healthcare professional (according to training requirements outlined on page 2) with experience in cancer treatment in that hospital
- Are prescribed and dispensed only sufficient medication for that cycle (i.e. until their next scheduled assessment)

**Patient education and information**

Equipping patients and carers to manage oral anticancer medications is vital to patient safety, patient concordance and treatment success. Cancer nurses and/or pharmacists with specialist anticancer medication knowledge can ensure that patients receive comprehensive education fit for their needs.\(^9\)

It is recommended that patient preparation takes place within dedicated specialist clinics. All cancer services should therefore urgently assess the potential role of nurse-led/pharmacist-led clinics in the management of patients prescribed oral anticancer therapies.\(^8,13\)

**Pre-treatment consultation**

Unique to oral anticancer medicines is the need to educate patients on self-administration of anticancer medication, including the principles of safe handling, storage and disposal, according to the chemotherapy services and Control of Substances Hazardous to Health (COSHH) Regulations 2002 (as amended).\(^9,14\) The pre-treatment consultation should be carried out by an appropriately trained healthcare professional (according to training requirements outlined on page 2) to ensure that patients fully understand how and when to take their oral anticancer medicines.\(^3\)

The pretreatment consultation should be structured and supported by nursing protocols and checklists, such as the Multinational Association for Supportive Care in Cancer (MASCC) oral agent teaching tool (MOATT).\(^15\) The consultation should be tailored to the individual patient’s needs, knowledge, perception and psychological status to enable them to self-manage their treatment. Understanding should be checked before the patient is given their oral medication.\(^9\) It is further recommended that expected patient response to serious side effects, such as neutropenic sepsis, are rehearsed with patients and carers and that key points are reviewed at the end of the consultation to ensure optimal management of complications.

The hospital should provide patients with comprehensive, evidence-based written, verbal and pictorial advice giving clear, unambiguous instructions about their oral anticancer medications. Full use should be made of NHS cancer websites to provide information for patients and carers to ensure the safe use of oral anticancer medicines.\(^1\) Patient alert cards\(^16\) and scheduling diaries\(^2\) are also useful when assisting patients to manage their own treatment. Patients should be encouraged to record side effects when they occur, and have this record with them when they are next assessed.

Topics for discussion (supported by written information) include the following:\(^3,9\)

- The intended oral anticancer regimen and treatment plan including, doses, route of administration, cycles intended, investigations, monitoring procedures, management of toxicities and any required supportive care measures or medications\(^1\)
- Local pathway for treatment and management of complications
- When and how to take the tablets correctly (e.g. with or before food)
- What to do in the event of missed doses
- What to do if patients vomit after taking a dose
• What side effects to expect and what to do about them:
  • Which symptoms can patients manage at home?
  • At what level of severity should they contact the hospital?
  • How side effects will be managed
  • Potential consequences of not presenting early with symptoms
  • Why and how to obtain further supplies
  • What role their GP/community nurses are expected to play in their treatment
  • Principles of safe handling, storage and disposal of medications and delivery devices (e.g. plastic spoons), and any implications for family members
  • Possible interactions with other drugs, supplements or herbal remedies

Key information points should be reinforced and holistic patient needs explored on subsequent visits.9

Consent

Chemotherapy nurses should be actively involved in the patient consent process and may legally take written consent from patients prescribed oral therapies if supported by local Trust policy. The British Committee for Standards in Haematology guidelines17 have been endorsed by NCEPOD7 to assist in the reduction in mortality rates within 30 days of systemic anticancer chemotherapy; they note that:17

“The healthcare professional carrying out the procedure is ultimately responsible for ensuring the patient is giving valid consent, and it is they who will be held responsible in law if this is challenged later. However, team-work is now the way the National Health Service operates and, where written consent is being sought, it may be appropriate for several members of the team to participate in the process of seeking consent. It is the responsibility of the healthcare professional to ensure that when he/she requires a colleague to seek consent on his/her behalf he/she is confident that the colleague will work within his/her own competence and will not agree to perform tasks which exceed that competence”

NCEPOD7 requires the consent process to include a clear outline of possible side effects, including those that are potentially life threatening. Consequently, standardised consent forms will be developed through a national work stream.

Access to 24-hour specialist oncology advice

Clinical chemotherapy services should provide a 24-hour telephone advice service for patients prescribed oral therapies, with appropriately trained nursing, medical or pharmacy staff handling queries.9 Patients can use such services to seek advice on anticancer medication management including side effects, and how to obtain help and treatment for them. It is important that this information is well presented and consistent with other information that the patients are given by the healthcare team.7

NCAG (2009) recommends that chemotherapy telephone advice lines should be supported by dedicated acute oncology services (AOS).8 These new services will encompass the management of patients who develop severe complications following chemotherapy, including neutropenic sepsis. Chemotherapy trained nurses have essential skills to support AOS’s and should actively engage/lead in their development.

Monitoring and follow up

Monitoring of patients who have been prescribed oral anticancer medicines is important for safe care because it helps to identify toxicities and complications early, allows prompt remedial actions and prevents serious complications and possible hospitalisation.7,8,13 Monitoring of patients may be particularly important for newer oral anticancer therapies, with novel modes of action as these may have unexpected side effects.18 Nurses should strongly consider establishing proactive targeted support services to identify problems before they become serious (e.g. using routine telephone monitoring).8,13

On-treatment assessment

All patients should be seen by a healthcare professional with specialist knowledge before every treatment cycle.9 For each patient, records should be made of the following:3
  • Continued ability to manage treatment at home, patient and carer needs and referral to other services
  • Performance status
  • Toxicity assessment, including grade, duration, management and relevance and any change in supportive medications
  • The results of essential serial investigations applicable to that cycle (and before administration within a cycle, if applicable)
  • Any dose modifications, and whether they are intended to be permanent
  • Any cycle (or administration) delays

After the final cycle of a treatment course, the record for each patient should include the following:3
  • Whether the course was completed or not
  • If the course was not completed or if the planned dose was reduced, the reasons for cessation or reduction
  • For completed courses of non-adjuvant treatment, a reference to the response
  • The plans for ongoing review and support

The role of the primary care team

The expanding availability of oral anticancer medicines means that communication with primary care and community health practitioners is increasingly important. Primary care nurses and GPs are among those who should be given precise and regular information on a patient’s treatment, potential side effects and drug interactions, where to get advice, where patients should report to and how they should be managed in the event of treatment complications, such
as the following:3,7
- Neutropenic sepsis
- Nausea and vomiting
- Stomatitis, other mucositis
- Palmar-plantar erythrodysesthesia
- Diarrhoea
- Hypertension
- Angina

There are increasing opportunities for shared care between secondary and primary care providers.8 While treatment is initiated by specialists, follow up and monitoring may be shared. Where shared care is in place, protocols and guidelines should be developed with primary care providers.

**Clinical governance**

Cancer service providers should develop robust quality improvement systems, to ensure that protocols and policies detailed in national guidance are developed, implemented and regularly audited.2,8 Each chemotherapy service should have regular morbidity/mortality meetings to review practice and policies and procedures in relation to the safety and quality of chemotherapy.7 Audit should include referral processes, e.g. management of treatment related emergencies and key outcomes of treatment.3 In addition, the cancer service provider should regularly review incidents and errors, and subsequent reports should be reviewed by the network chemotherapy group and local governance forums.8

This position statement will be reviewed by oncology nurses from the UK Oncology Nursing Society in 2012, or sooner if warranted.

**Acknowledgement**

Editorial support was provided by Abbie Pound of Succinct Healthcare Communications.

**References**


UKONS
Oncology Nursing Society

“The nation’s cancer nurses”

What’s in it for you?

- A prominent, collective voice for cancer nursing that is based on fully consultative and interactive membership
- Your views and expertise will be sought and shared with peers, cancer nurse leaders and national strategic policy makers in every country of the UK
- Your collective voice will influence the future of cancer nursing to ensure nursing practice is informed and developed by practising nurses
- Local and national study days, conferences and local fora to promote excellence in nursing and influence cancer policy
- Educational awards are available to members
- New interactive website, offering members only areas
- Associate membership available to AHPs (no voting rights)
- Associated member of European Oncology Nursing Society (EONS) which qualifies UKONS members for certain EONS membership benefits
- Payment can be made by direct debit

Join or renew your membership ONLINE at www.ukons.org/join

If you’re a UKONS member, why not get involved in one of our forums?

Living With & Beyond Cancer Forum
- Participate in setting the benchmark for the care of people living with and beyond cancer
- Establishment of topic-specific working groups
- Formulation of a priorities workplan
Contact either Natalie Doyle (Natalie.Doyle@mhh.nhs.uk) or Mhairi Simpson (Mhairi.Simpson@lanarkshire.scot.nhs.uk).

Genetics in Cancer Forum
- Raise awareness of the importance of genetics in meeting the needs of patients and their families
- Debate and exchange best practice information on issues related to genetics in cancer nursing and develop work streams to move the genetic nursing agenda forward through UKONS
- Inform and influence policies, practice and education, service delivery and organisation where cancer genetics is relevant
- Identify areas for future development in education, resources and practice
Contact either Cheryl Vidall (cherylv@hah.co.uk) or Richard Henry (rhenry@qub.ac.uk).

Chemotherapy Forum
- Update on the forum’s achievements over the past year
- Availability of support for meetings
- Regional forum round ups from the chairs/vice chairs
- How UKONS can assist your forum in completing your work programme
- Way forward for the next year - in light of NCAG & NCEPOD
Contact either Helen Roe (helen.roe@cumbria-acute.nhs.uk) or Elaine Lennan (elaine.lennan@suht.swest.nhs.uk).

Date of preparation: September 2010